Magnesium ammonium phosphate cement composition

• US 6,908,506 B2
• Filed: 02/04/2004
• Issued: 06/21/2005
• Est. Priority Date: 07/03/2000
• Status: Expired due to Term

• Current Assignee: Kyphon SARL (Medtronic Plc)
• Original Assignee: Kyphon Incorporated (Medtronic Plc)
• Inventors: Zimmermann, Michael
• Primary Examiner(s): Wood, Elizabeth D.
• Application Number:
  US10/772,857
• Publication Number:
  US 20040173122A1
• Time in Patent Office: 503 Days
• Field of Search: 106/35, 106/690, 106/691, 106/696
• US Class Current: 106/696
• CPC Class Codes: A61B 17/00491 Surgical glue applicators surgical adhesives A61L24/00; two-component delivery syringes A61M5/19
• CPC Class Codes: A61F 2/28 Bones joints A61F2/30
• CPC Class Codes: A61F 2002/30062 (bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
• CPC Class Codes: A61F 2002/30535 Special structural features of bone or joint prostheses not otherwise provided for
• CPC Class Codes: A61F 2002/4631 the prosthesis being specially adapted for being cemented
• CPC Class Codes: A61F 2210/0004 bioabsorbable
• CPC Class Codes: A61F 2250/0058 Additional features; Implant or prostheses properties not otherwise provided for
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/42 Phosphorus; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 6/17 Particle size
• CPC Class Codes: A61K 6/838 Phosphorus compounds, e.g. apatite
• CPC Class Codes: A61K 6/864 Phosphate cements apatite A61K6/838
• CPC Class Codes: A61K 6/867 Ammonium cements
• CPC Class Codes: A61L 24/0036 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61L 24/02 containing inorganic materials
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 27/12 Phosphorus-containing materials, e.g. apatite
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: C04B 12/025 : Phosphates of ammonium or of the alkali or alkaline earth metals
• CPC Class Codes: C04B 14/22 : Glass ; Devitrified glass
• CPC Class Codes: C04B 14/26 : Carbonates
• CPC Class Codes: C04B 14/30 : Oxides other than silica ferrites C04B14/363
• CPC Class Codes: C04B 14/304 : Magnesia
• CPC Class Codes: C04B 14/366 : Phosphates, e.g. apatite
• CPC Class Codes: C04B 20/008 : Micro- or nanosized fillers, e.g. micronised fillers with particle size smaller than that of the hydraulic binder colloidal silica C04B14/062 ; silica fume C04B18/146
• CPC Class Codes: C04B 2103/0009 : Inorganic ammonium compounds
• CPC Class Codes: C04B 2111/00206 : Compositions defined by their elemental analysis
• CPC Class Codes: C04B 2111/00836 : for medical or dental applications
• CPC Class Codes: C04B 22/06 : Oxides, Hydroxides C04B22/0013 takes precedence
• CPC Class Codes: C04B 22/062 : of the alkali or alkaline-earth metals
• CPC Class Codes: C04B 22/064 : of the alkaline-earth metals
• CPC Class Codes: C04B 22/10 : containing carbon in the anion
• CPC Class Codes: C04B 22/124 : Chlorides of ammonium or of the alkali or alkaline earth metals, e.g. calcium chloride
• CPC Class Codes: C04B 22/126 : Fluorine compounds, e.g. silico-fluorine compounds
• CPC Class Codes: C04B 22/142 : Sulfates
• CPC Class Codes: C04B 22/143 : Calcium-sulfate
• CPC Class Codes: C04B 22/16 : containing phosphorus in the anion, e.g. phosphates
• CPC Class Codes: C04B 24/10 : Carbohydrates or derivatives thereof
• CPC Class Codes: C04B 24/282 : Polyurethanes; Polyisocyanates
• CPC Class Codes: C04B 28/34 : containing cold phosphate binders
• CPC Class Codes: C04B 28/344 : the phosphate binder being present in the starting composition solely as one or more phosphates
• CPC Class Codes: C04B 28/346 : the phosphate binder being present in the starting composition as a mixture of free acid and one or more phosphates
• CPC Class Codes: C04B 28/348 : the starting mixture also containing one or more reactive oxides

Abstract

This invention relates to a cement, which comprises in its main phase of microcrystalline magnesium ammonium phosphate and nanoapatite after hardening and thus at the same time has considerable strength. The material is biologically degradable and is suitable for application in tooth cements, as bone replacement, as bone filler, as bone cement or as bone adhesive.

Claims

1. A magnesium ammonium phosphate cement preparation comprising:

a powder mixture having molar quantities of the components calcium (Ca), magnesium (Mg) and orthophosphate (P) in the mixture in the ranges 1<

Ca/P<

1.5 and Mg/P<

0.5; and

an ammonium salt.

2. The preparation according to claim 1, wherein the ammonium salt comprises an aqueous solution having a pH in the range from 7 to 12.

3. The preparation according to claim 1, wherein the ammonium salt is present in the powder mixture at molar quantity of ammonium (NH₄) less than 0.5.

4. The preparation according to claim 1, wherein the powder mixture comprises α

/β

-tertiary calcium phosphate (α

/β

-TCP).

5. The preparation according to claim 4, wherein the powder mixture further comprises MgHPO₄.3H₂O.

6. The preparation according to claim 5, wherein the powder mixture further comprises Mg₃(PO₄)₂.

7. The preparation according to claim 1, wherein the powder mixture comprises (NH₄)₂SO₄.

8. The preparation according to claim 1, wherein the powder mixture further comprises KH₂PO₄.

9. The preparation according to claim 1, wherein the powder mixture further comprises Na₂HPO₄.

10. The preparation according to claim 1, further comprising SrCO₃.

11. The preparation according to claim 10, wherein the SrCO₃ is present in the range of 0.01 to 10 wt. % based on the total weight of the preparation.

12. The preparation according to claim 10, wherein the SrCO₃ is present in the range of 0.1 to 5 wt. % based on the total weight of the preparation.

13. The preparation according to claim 1, further comprising ZnO.

14. The preparation according to claim 1, wherein the powder mixture further comprises Ca₂NaK(PO₄)₂ and/or CaKPO₄.

15. The preparation according to claim 1, further comprising a fluoride.

16. The preparation according to claim 1, further comprising a pharmaceutical and/or a bioactive active ingredient.

17. The preparation according to claim 16, wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.

18. A magnesium ammonium phosphate cement preparation comprising:

a powder mixture comprising α

-TCP, β

-TCP, MgHPO4.3H₂O, KH₂PO₄ and Na₂HPO₄; and

an ammonium salt.

19. The preparation according to claim 18, wherein the powder mixture further comprises SrCO₃.

20. The preparation according to claim 19, wherein the SrCO₃ is present in a quantity of 0.01 to 10 wt. % based on the total weight of the preparation.

21. The preparation according to claim 18, further comprising ZnO.

22. The preparation according to claim 18, wherein the powder mixture further comprises Ca₂NaK(PO₄)₂ and/or CaKPO₄.

23. The preparation according to claim 18, further comprising a fluoride.

24. The preparation according to claim 18, further comprising a pharmaceutical and/or a bioactive active ingredient.

25. The preparation according to claim 24, wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.

26. A magnesium ammonium phosphate cement preparation comprising:

a powder mixture comprising α

-TCP, β

-TCP, (NH₄)₂SO₄, KH₂PO₄ and Na₂HPO₄; and

a magnesium salt.

27. The preparation according to claim 26, wherein the magnesium salt is MgHPO₄.3H₂O.

28. The preparation according to claim 26, wherein the powder mixture further comprises SrCO₃.

29. The preparation according to claim 28, wherein the SrCO₃ is present at 0.01 to 10 wt. % based on the total weight of the preparation.

30. The preparation according to claims 26, further comprising ZnO.

31. The preparation according to claims 26, wherein the powder mixture further comprises Ca₂NaK(PO₄)₂ and/or CaKPO₄.

32. The preparation according to claim 26, further comprising a fluoride.

33. The preparation according to claim 26, further comprising a pharmaceutical and/or a bioactive active ingredient.

34. The preparation according to claim 33, wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.

35. A magnesium ammonium phosphate cement preparation comprising:

a powder mixture comprising α

-TCP, β

-TCP, primary or secondary ammonium phosphate, KH₂PO₄ and Na₂HPO₄; and

a magnesium salt.

36. The preparation according to claim 35, wherein the magnesium salt is MgHPO₄.3H₂O.

37. The preparation according to claim 35, wherein the powder mixture further comprises SrCO₃.

38. The preparation according to claim 37, wherein the SrCO₃ is present at 0.01 to 10 wt. % based on the total weight of the preparation.

39. The preparation according to claim 35, further comprising ZnO.

40. The preparation according to claim 35, wherein the powder mixture further comprises Ca₂NaK(PO₄)₂ and/or CaKPO₄.

41. The preparation according to claim 35, further comprising a fluoride.

42. The preparation according to claim 35, further comprising a pharmaceutical and/or a bioactive active ingredient.

43. The preparation according to claim 42, wherein the pharmaceutical and/or a bioactive active ingredient comprises a therapeutic dose of a component selected from the group consisting of antibiotics, cytostatic agents, analgesics, disinfectants, growth factors, proteins or elastin inhibitors.